Skip to main content
Clinical Trials/NCT01380886
NCT01380886
Completed
Phase 3

Growth and Tolerance of Young Infants Fed Infant Formulas

Abbott Nutrition12 sites in 1 country209 target enrollmentJune 2011
ConditionsInfant Newborn

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Infant Newborn
Sponsor
Abbott Nutrition
Enrollment
209
Locations
12
Primary Endpoint
Weight gain
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

This is a randomized, multi-center, double blind, parallel study to compare growth and tolerance of healthy term infants fed either control or experimental infant formula.

Registry
clinicaltrials.gov
Start Date
June 2011
End Date
December 2011
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • healthy infant
  • full term
  • birth weight \> 2490 g
  • 0 to 8 days of age
  • parent/physician agree to not use medications affecting tolerance/growth
  • parent agrees to sole source feeding of study formula
  • parent agrees to not use vitamin/mineral supplements
  • parent has signed consent/HIPAA authorization

Exclusion Criteria

  • any maternal, fetal, or infant history affecting growth and tolerance
  • participation in any other study not preapproved by Abbott

Outcomes

Primary Outcomes

Weight gain

Time Frame: 119 days

Secondary Outcomes

  • gastrointestinal tolerance(119 days)
  • Anthropometric variables(119 days)

Study Sites (12)

Loading locations...

Similar Trials